Phio Pharmaceuticals Corp.
PHIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3,643 | $6,332 | $7,012 | $8,886 |
| Gross Profit | -$3,643 | -$6,332 | -$7,012 | -$8,886 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,643 | $6,332 | $7,012 | $8,886 |
| G&A Expenses | $3,744 | $4,288 | $4,450 | $4,625 |
| SG&A Expenses | $3,744 | $4,288 | $4,450 | $4,625 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,643 | -$6,128 | -$7,012 | -$8,886 |
| Operating Expenses | $3,744 | $4,492 | $4,450 | $4,625 |
| Operating Income | -$7,387 | -$10,824 | -$11,462 | -$13,511 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $237 | -$2 | -$18 | $224 |
| Pre-Tax Income | -$7,150 | -$10,826 | -$11,480 | -$13,287 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,150 | -$10,826 | -$11,480 | -$13,287 |
| % Margin | – | – | – | – |
| EPS | -0.91 | -46.87 | -89.61 | -111.32 |
| % Growth | 98.1% | 47.7% | 19.5% | – |
| EPS Diluted | -0.91 | -46.76 | -89.61 | -111.32 |
| Weighted Avg Shares Out | 7,875 | 231 | 126 | 119 |
| Weighted Avg Shares Out Dil | 7,875 | 232 | 126 | 119 |
| Supplemental Information | – | – | – | – |
| Interest Income | $231 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $184 | $71 | $75 |
| EBITDA | -$7,385 | -$10,642 | -$11,391 | -$13,436 |
| % Margin | – | – | – | – |